The Hammer and the Dance: Where Healthcare Investment Goes Next Under COVID-19 | FreeS Fund
The unexpected arrival of COVID-19 turned out to be a shot in the arm for the healthcare industry.
Articles
Why Is "New Infrastructure" China's Most Consequential Stimulus Policy for the Next Decade? | Li Feng Column
Two Decades of Chinese Infrastructure: The Evolution of Stimulus Policy and the Industry Chain's Long March
Shuimu BioSciences Announces Angel Round to Build World-Class Next-Generation Drug Discovery Platform
Shuimu BioSciences has built Asia's first commercial protein structure analysis platform centered on 300kV top-tier cryo-EM, dedicated to using breakthrough technology to dramatically accelerate drug discovery and improve the druggability of difficult targets.
FreeS Fund received eight recognitions from institutions including *Fortune* (Chinese edition), 36Kr, and the Fund of Funds Alliance.
Do what's right, not what's easy.
Leading nanopore gene sequencing company **Qitan Technology** has raised over RMB 100 million in funding, led by Gaorong Ventures.
Focused on the independent R&D of nanopore gene sequencers, dedicated to making gene sequencing technology accessible to every household.
A Visual Guide to China's Industrial Chain Shifts and Opportunities | Li Feng Column
The 40-Year Metamorphosis of China's Industrial Chain
MemVerge Secures $19 Million Strategic Investment to Accelerate the "Big Memory Computing" Era
Intel, Cisco, NetApp, and SK hynix — industry leaders — have joined forces to invest, spearheading the big memory revolution.
Source Code Capital portfolio company YiCan announced the completion of a multi-million-dollar Pre-A funding round, with existing investor Source Code Capital continuing to increase its stake.
The company serves nearly 1,000 clients, with 70% being post-Series A companies or those generating annual revenue exceeding RMB 20 million.
Growth, Growth, Growth, Growth, Growth, Growth, Growth, Growth, Growth
Grow Into Who You Are
Gaorong Bulletin · April | Gaorong Ventures Actively Responds to "Zhongguancun Venture Capital Anti-Epidemic Investment Initiative," Joins First Batch of China Equity Investment Fund Managers' Creditworthy Red List
"We are firmly bullish on China, and we believe that steadfastly investing in technology and innovation-driven industries represents the greatest opportunity looking ahead."